tetano
Editor, Senior Moderator
Lancet Reg Health Am
. 2023 Feb;18:100403.
doi: 10.1016/j.lana.2022.100403. Epub 2022 Dec 2.
Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022
Ryan E Wiegand[SUP] 1 [/SUP], Yangyang Deng[SUP] 2 [/SUP], Xiaoyi Deng[SUP] 2 [/SUP], Adam Lee[SUP] 2 [/SUP], William A Meyer 3rd[SUP] 3 [/SUP], Stanley Letovsky[SUP] 4 [/SUP], Myrna D Charles[SUP] 1 [/SUP], Adi V Gundlapalli[SUP] 1 [/SUP], Adam MacNeil[SUP] 1 [/SUP], Aron J Hall[SUP] 1 [/SUP], Natalie J Thornburg[SUP] 1 [/SUP], Jefferson Jones[SUP] 1 [/SUP], Ronaldo Iachan[SUP] 2 [/SUP], Kristie E N Clarke[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Sero-surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can reveal trends and differences in subgroups and capture undetected or unreported infections that are not included in case-based surveillance systems.
Methods: Cross-sectional, convenience samples of remnant sera from clinical laboratories from 51 U.S. jurisdictions were assayed for infection-induced SARS-CoV-2 antibodies biweekly from October 25, 2020, to July 11, 2021, and monthly from September 6, 2021, to February 26, 2022. Test results were analyzed for trends in infection-induced, nucleocapsid-protein seroprevalence using mixed effects models that adjusted for demographic variables and assay type.
Findings: Analyses of 1,469,792 serum specimens revealed U.S. infection-induced SARS-CoV-2 seroprevalence increased from 8.0% (95% confidence interval (CI): 7.9%-8.1%) in November 2020 to 58.2% (CI: 57.4%-58.9%) in February 2022. The U.S. ratio of the change in estimated seroprevalence to the change in reported case prevalence was 2.8 (CI: 2.8-2.9) during winter 2020-2021, 2.3 (CI: 2.0-2.5) during summer 2021, and 3.1 (CI: 3.0-3.3) during winter 2021-2022. Change in seroprevalence to change in case prevalence ratios ranged from 2.6 (CI: 2.3-2.8) to 3.5 (CI: 3.3-3.7) by region in winter 2021-2022.
Interpretation: Ratios of the change in seroprevalence to the change in case prevalence suggest a high proportion of infections were not detected by case-based surveillance during periods of increased transmission. The largest increases in the seroprevalence to case prevalence ratios coincided with the spread of the B.1.1.529 (Omicron) variant and with increased accessibility of home testing. Ratios varied by region and season with the highest ratios in the midwestern and southern United States during winter 2021-2022. Our results demonstrate that reported case counts did not fully capture differing underlying infection rates and demonstrate the value of sero-surveillance in understanding the full burden of infection. Levels of infection-induced antibody seroprevalence, particularly spikes during periods of increased transmission, are important to contextualize vaccine effectiveness data as the susceptibility to infection of the U.S. population changes.
Funding: This work was supported by the Centers for Disease Control and Prevention, Atlanta, Georgia.
Keywords: COVID-19; SARS-CoV-2; Seroprevalence; United States.
. 2023 Feb;18:100403.
doi: 10.1016/j.lana.2022.100403. Epub 2022 Dec 2.
Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022
Ryan E Wiegand[SUP] 1 [/SUP], Yangyang Deng[SUP] 2 [/SUP], Xiaoyi Deng[SUP] 2 [/SUP], Adam Lee[SUP] 2 [/SUP], William A Meyer 3rd[SUP] 3 [/SUP], Stanley Letovsky[SUP] 4 [/SUP], Myrna D Charles[SUP] 1 [/SUP], Adi V Gundlapalli[SUP] 1 [/SUP], Adam MacNeil[SUP] 1 [/SUP], Aron J Hall[SUP] 1 [/SUP], Natalie J Thornburg[SUP] 1 [/SUP], Jefferson Jones[SUP] 1 [/SUP], Ronaldo Iachan[SUP] 2 [/SUP], Kristie E N Clarke[SUP] 1 [/SUP]
Affiliations
- PMID: 36479424
- PMCID: PMC9716971
- DOI: 10.1016/j.lana.2022.100403
Abstract
Background: Sero-surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can reveal trends and differences in subgroups and capture undetected or unreported infections that are not included in case-based surveillance systems.
Methods: Cross-sectional, convenience samples of remnant sera from clinical laboratories from 51 U.S. jurisdictions were assayed for infection-induced SARS-CoV-2 antibodies biweekly from October 25, 2020, to July 11, 2021, and monthly from September 6, 2021, to February 26, 2022. Test results were analyzed for trends in infection-induced, nucleocapsid-protein seroprevalence using mixed effects models that adjusted for demographic variables and assay type.
Findings: Analyses of 1,469,792 serum specimens revealed U.S. infection-induced SARS-CoV-2 seroprevalence increased from 8.0% (95% confidence interval (CI): 7.9%-8.1%) in November 2020 to 58.2% (CI: 57.4%-58.9%) in February 2022. The U.S. ratio of the change in estimated seroprevalence to the change in reported case prevalence was 2.8 (CI: 2.8-2.9) during winter 2020-2021, 2.3 (CI: 2.0-2.5) during summer 2021, and 3.1 (CI: 3.0-3.3) during winter 2021-2022. Change in seroprevalence to change in case prevalence ratios ranged from 2.6 (CI: 2.3-2.8) to 3.5 (CI: 3.3-3.7) by region in winter 2021-2022.
Interpretation: Ratios of the change in seroprevalence to the change in case prevalence suggest a high proportion of infections were not detected by case-based surveillance during periods of increased transmission. The largest increases in the seroprevalence to case prevalence ratios coincided with the spread of the B.1.1.529 (Omicron) variant and with increased accessibility of home testing. Ratios varied by region and season with the highest ratios in the midwestern and southern United States during winter 2021-2022. Our results demonstrate that reported case counts did not fully capture differing underlying infection rates and demonstrate the value of sero-surveillance in understanding the full burden of infection. Levels of infection-induced antibody seroprevalence, particularly spikes during periods of increased transmission, are important to contextualize vaccine effectiveness data as the susceptibility to infection of the U.S. population changes.
Funding: This work was supported by the Centers for Disease Control and Prevention, Atlanta, Georgia.
Keywords: COVID-19; SARS-CoV-2; Seroprevalence; United States.